Non-Alcoholic Steatohepatitis Research Study
Researchers at the Medical University of South Carolina are partnering with individuals diagnosed with non-alcoholic steatohepatitis (NASH) to evaluate whether treatment with semaglutide can help. Join our compensated study today!
Fast Facts
diagnosed with NASH
diagnosed with fibrosis stage 2 or 3
18 Years and Older
Compensation Provided
Conducted in South carolina
Study Background
Semaglutide is a well-known medicine that is already used by doctors to treat type 2 diabetes in many countries. It is now being studied as a treatment for non-alcoholic steatohepatitis (NASH). In this 5-year study, we want to see if treatment with semaglutide can improve NASH and liver fibrosis.
If you participate, you will either receive semaglutide or a dummy medicine. Which treatment you get is decided by random chance. You will need to inject yourself with medicine under the skin once a week. You will also have up to 21 clinic visits and 9 phone calls with the clinical staff during the study.
Your participation in this study may help researchers improve treatment approaches for NASH. Advance research today and join our compensated study!
Study Background
Semaglutide is a well-known medicine that is already used by doctors to treat type 2 diabetes in many countries. It is now being studied as a treatment for non-alcoholic steatohepatitis (NASH). In this 5-year study, we want to see if treatment with semaglutide can improve NASH and liver fibrosis.
If you participate, you will either receive semaglutide or a dummy medicine. Which treatment you get is decided by random chance. You will need to inject yourself with medicine under the skin once a week. You will also have up to 21 clinic visits and 9 phone calls with the clinical staff during the study.
Your participation in this study may help researchers improve treatment approaches for NASH. Advance research today and join our compensated study!
Additional Information
You may qualify for this study if you meet the following criteria.
Key Criteria:
- 18+ years old
- Diagnosed with non-alcoholic steatohepatitis (NASH)
- Diagnosed with Fibrosis stage 2 or 3
- No evidence of other causes of liver disease
- No excessive consumption of alcohol
- Not pregnant, breastfeeding, or planning to become pregnant
If you consent to participate in this study, you will have at least 21 clinic visits and at least 9 phone calls with the clinical staff. The phone calls will be approximately 15-20 minutes in length. There will be 14 short visits (about one hour), and 7 long (about 1-3 hours) visits. Some of the longer clinic visits may be spread over more than one day, which could result in more visits. This will happen only if procedures are necessary that cannot be scheduled on the day your scheduled visit is required. The study staff will work hard to make sure all procedures required for a scheduled visit can be scheduled the same day, or let you know prior to the scheduled visit.
This study will take place over approximately 5 years (or 257 weeks), with study visits occurring every 4-24 weeks, depending on the stage of the study. You will attend 11 clinic visits from the time of randomization until week 78. After week 78, clinic visits will be every 24 weeks. The study team will also be calling you in between clinic visits to check-in. This will help to make sure you have all questions answered.
You will be paid $75.00 for each completed clinic visit. If you complete the entire study, you may receive up to $2,250. If you travel more than 60 miles round trip to the study site, you will be eligible for reimbursement for travel and/or overnight stay expenses for up to $350 per visit. You will be paid $150.00 for each liver biopsy. You could have up to three liver biopsies during the course of the study.